Imagine the impact. #KnowTheScore #AlopeciaAreata #AAD2023

Today we shared our second quarter 2023 financial results, as well as recent company updates and upcoming milestones. Learn more about the progress we’ve made on our ambitious plans to build a best-in-class, fully integrated global medicines company here: bit.ly/3q8vBWx

We're honored to share that Kymera has been recognized as a #TopPlacetoWork in Massachusetts by the The Boston Globe for the second year in a row! Our shared values and deep commitment to helping patients are the foundation of our culture and connect us to Kymera’s mission. Hear from

Today at our R&D Day, we're excited to share an overview of our strategy to build an industry leading #immunology pipeline of oral degrader medicines with the potential to transform treatment paradigms. And we're thrilled to unveil two first-in-class programs targeting STAT6 and

We're thrilled that our first-in-class oral IRAK4 degrader, KT-474, the first clinical heterobifunctional degrader in #immunology, has been nominated as a finalist for Molecule of the Year by @drughuntersite! Don't forget to vote! bit.ly/3T5kJmJ #TPD #DrugDiscovery

When Kymera Therapeutics signed the lease at Arsenal on the Charles, there wasn't even a building yet, so they were able to design the space with an architect. Check out photos of its new lab and office space. bizjournals.com/boston/news/20…

Our Head of Research, Juliet Williams, was featured today in Drug Target Review's #WomenInSTEM series! She reflects on her career leading highly productive scientific teams in novel #drugdiscovery research and shares key learnings and advice for women looking to pursue careers in

Thank you Brad Loncar for featuring our CEO Nello Mainolfi on @BiotechTVHQ to discuss our exciting achievements over the past year and how we’re harnessing the power of #TPD to develop differentiated medicines with the potential to address critical health problems and improve

We have been barrier breakers in our quest to target #STAT6. KT-621, our STAT6 degrader, has the potential to provide biologics-like activity with an oral small molecule profile for numerous #Th2 driven immuno-inflammatory diseases, and we’re thrilled to be the first company to

#ICYMI Check out our CEO Nello Mainolfi's recent blog on the ground breaking work done by the Kymera team to advance KT-621, our oral #STAT6 degrader with the potential to be a paradigm shifting medicine and change how #Th2 immuno-inflammatory diseases can be treated:

We're honored to be recognized and featured as a #TopPlacetoWork in Massachusetts by the The Boston Globe for a third consecutive year! This recognition is a testament to our team’s dedication to scientific excellence, genuine camaraderie, and commitment to improving lives. And we

2024 has been a year of #innovation and #excellence. We’ve made incredible progress advancing our industry leading #immunology portfolio of next generation oral drugs with potentially first-in-class profiles. We’re energized by the opportunity we have before us as we continue on

The status-quo for immunology drugs is about to change. Learn more in our latest blog by Arsalan Shabbir, VP of Clinical Development, about how targeting #STAT6 is just the beginning in: “A Revolution in Immunology: Creating New Possibilities with Oral Medicines”

“I was inspired to join this mission, leveraging my understanding of the patient experience in #immunology to contribute to breakthroughs that redefine what’s possible in this therapeutic area.” Hear more about how the Kymera team has opened new possibilities by targeting #STAT6

We recently celebrated our annual #Culture Week to recognize our team’s dedication to scientific excellence, genuine camaraderie, and commitment to improving patients’ lives – check out the festivities below! And we invite like-minded innovators to join us on our extraordinary

Hear from Juliet Williams, our Head of Research, in her new blog on how Kymera is expanding possibilities in #immunology by tackling coveted undrugged targets like #STAT6 with oral degrader medicines: bit.ly/4cQ9Crd #RevolutionizingImmunology #TPD #PatientImpact

𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: Kymera Therapeutics Founder & CEO Nello Mainolfi discusses the safety, degradation, and biomarker profile he sees in the company's STAT6 healthy volunteer data. $KYMR Full video: biotechtv.com/post/kymera-th…

An unforgettable moment ringing the Nasdaq Exchange opening bell with this incredible team! #RevolutionizingImmunology #NasdaqListed

Our team is heading to Paris this week for the #EADVCongress! We’re excited to connect with fellow innovators in the #dermatology community and share presentations on our groundbreaking work to advance novel oral degrader medicines. Hope to see you there!

Thank you BioCentury and Selina Koch for featuring our Founder & CEO, Nello Mainolfi, on the #BioCenturyShow. In this episode, Nello discusses the science and strategy of #TargetedProteinDegradation—its unique catalytic mechanism, ability to reach historically undrugged